Investment
Features
FeesSafety
Academy
More
Pluang+

Sentora's OUSD vault holds $43M but sees almost no borrowing, limiting yield for depositors.

Protocol Fundamentals
19 Oct 2026
Crypto Briefing
View Source
Neutral
Sentora's OUSD vault holds $43M but sees almost no borrowing, limiting yield for depositors.

Sentora's new OUSD lending vault on the Tempo blockchain has attracted about $42.5 to $43 million in deposits since its launch in mid-October 2026. However, borrowing activity is extremely low, with loans dropping to as little as 4.51 OUSD, meaning most deposited funds remain idle and do not generate interest from lending. Borrowers would need to post Coinbase Wrapped Bitcoin (cbBTC) as collateral to draw OUSD, but demand is weak. As a result, depositors earn nearly zero organic yield, relying mainly on temporary external rewards offering around 3.6% APR. This situation highlights limited current appetite for borrowing OUSD despite significant deposits, and future yield depends on increased borrowing or continued incentives.

Sentora's OUSD lending vault on the Tempo blockchain holds about $43 million in deposits but sees minimal borrowing activity. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 20, 2026 03:42 WIB: out of 50 major cryptocurrencies priced on Pluang, 46 rose and 3 fell. Notable movers include BAT at Rp3.556 with a 17.84% increase and balanced buy/sell activity, BAL at Rp16.297 up 11.14%, and CRV at Rp6.517 with a 9.94% rise but predominantly sell orders. The most notable figure is BAT's 17.84% gain.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
30 minutes ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
30 minutes ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
1 hour ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
2 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App